Top Markets
#1 Nesa Nesa +801.92%
#2 Cortex Cortex +68.10%
#3 Merlin's Seal BTC Merlin's Seal BTC +45.20%
#4 Pons Pons +26.22%
#5 QuantixAI QuantixAI +23.95%
#6 EXOD EXOD +22.78%
#7 Instadapp Instadapp +18.46%
#8 Movement Movement +12.71%
#9 Magma Finance Magma Finance +11.78%
#10 SkyAI SkyAI +11.58%
Coin of the day
Nesa Nesa
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Reata Pharmaceuticals, Inc. Reata Pharmaceuticals, Inc.

Reata Pharmaceuticals, Inc.

RETA
Classifica tra le azioni #3255
Reata Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company... Reata Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to discovering, developing, and commercializing innovative therapies for individuals afflicted with severe or life-threatening illnesses. A key focus is bardoxolone methyl (often referred to as bardoxolone), which is currently undergoing Phase 3 clinical trials for two distinct conditions: chronic kidney disease (CKD) associated with Alport syndrome, and a specific type of pulmonary arterial hypertension linked to connective tissue diseases. Bardoxolone also has an offering for autosomal dominant polycystic kidney disease (ADPKD). The pipeline further includes omaveloxolone, currently in Phase II development for Friedreich's ataxia. Reata is also advancing Phase 2 studies for various other chronic kidney diseases, such as IgA nephropathy, type 1 and type 2 diabetic CKD, hypertensive CKD, and focal segmental glomerulosclerosis, among others. Beyond these, the company's earlier-stage development includes RTA 901, aimed at neurological disorders, and RTA 1701, which holds potential for treating a spectrum of autoimmune, inflammatory, and fibrotic conditions. The company has established strategic partnerships, including an agreement with Kyowa Kirin Co., Ltd. for the development and commercialization of bardoxolone across various renal, cardiovascular, diabetes, and metabolic indications within a broad territory spanning Japan, China, Hong Kong, Macao, South Korea, Taiwan, and several Southeast Asian nations (Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia). Additionally, Reata collaborates with AbbVie Inc. to jointly research, develop, and commercialize second- and later-generation Nrf2 activators for all indications excluding renal, cardiovascular, and metabolic applications. Originally incorporated in 2002 as Reata Discovery, Inc., the company officially became Reata Pharmaceuticals, Inc. in May 2005. It is headquartered in Plano, Texas.
Prezzo delle azioni
$172.36
Ultima sincronizzazione: 2023-09-26
Capitalizzazione di mercato
$5.81B
Variazione (1 giorno)
0.00%
Variazione (1 anno)
0.00%
Paese
US
Scambia Reata Pharmaceuticals, Inc. (RETA)

Categoria

Healthcare
Storico dividendi per Reata Pharmaceuticals, Inc. (RETA)
Reata Pharmaceuticals, Inc. (simbolo azionario: RETA) ha effettuato un totale di 0 pagamenti di dividendi.
La somma totale dei dividendi (rettificata per split azionari) è: 0.00
Rendimento da dividendo (TTM): 0
Pagamenti dei dividendi per Reata Pharmaceuticals, Inc. (RETA) dal 2026 al 2026
Pagamenti annuali dei dividendi
Anno Dividendo (rettificato per split azionari) Cambia
Non abbastanza dati per le date fornite.
Elenco di tutti i pagamenti di dividendi
Anno Dividendo Cambia
Non abbastanza dati per le date fornite.
Dividendi di aziende simili o concorrenti
Azienda Numero di pagamenti di dividendi Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
0.00%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
0.00%
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
0.00%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
64.00%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00%
CH